Commercial Director, Centre for Process Innovation
Originally starting as a lab chemist developing novel routes to pharmaceuticals for UK biotech company Chirotech, Nick moved to project and product management for a range of key technologies. That business was eventually bought by the Dow Chemical Company and Nick was supported to study for a master of business administration. That marked a shift in his career, with Nick moving into his first fully-commercial role undertaking business development for highly specialised DNA-based therapies and later leading business development in Japan.
The Chirotech business was subsequently sold to Dr Reddy’s, a major generic pharmaceutical company based in India, where Nick headed the commercial group in the UK, which included a research and development site in Cambridge and manufacturing base in West Yorkshire. From Dr Reddy’s he joined Sigma Aldrich, to lead the global marketing for their pharmaceutical contract manufacturing business, which encompassed 13 sites in the UK, Ireland, Israel, Switzerland and the US. He then took on the lead for strategy and marketing role for Catalent’s advanced delivery technologies division.
Catalent is a leading provider of pharmaceutical dose form services to the pharmaceutical industry, which include tablets, capsules, syringes and sophisticated drug delivery technologies. Most recently before joining CPI, Nick was leading strategic marketing for global specialty chemical company Johnson Matthey’s health sector. Its health sector provides a broad array of pharmaceutical active ingredients and contract manufacturing solutions to a wide range of pharma companies.
He holds a first-class batchelor of science degree from the University of Manchester Institute of Science and Technology and a PhD in organic chemistry from the same organisation. His master of business administration was gained at Imperial College and he is also a Fellow of the Royal Society of Chemistry.
16 November 2020
BOOK YOUR PLACE NOW